Vaccine for Acute Myeloid Leukemia?

(August 14, 2019)

A personalized cancer vaccine markedly improved outcomes for patients suffering from acute myeloid leukemia (AML), a potentially lethal blood cancer, in a clinical trial led by investigators at Beth Israel Deaconess Medical Center (BIDMC). The product... Continue Reading


FDA approves darolutamide for non-metastatic castration-resistant prostate cancer

(August 1, 2019)

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer On July 30, 2019, the Food and Drug Administration approved darolutamide (NUBEQA, Bayer HealthCare Pharmaceuticals Inc.) for non-metastatic castration-resistant prostate... Continue Reading


Dana-Farber Opens New Clinical Trials for Patients with Endometrial Cancer

(July 30, 2019)

A recent dearth of clinical trials of treatments for endometrial cancer has segued into a research revival – including four new trials led by Dana-Farber investigators – spurred by advances in the scientific understanding of the disease. The trials... Continue Reading


FDA Approves Ruxience Biosimlar to Rituxan

(July 25, 2019)

The FDA approved rituximab-pvvr, a rituximab biosimilar, for use alone or in combination with chemotherapy for the treatment of adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as granulomatosis... Continue Reading


FDA grants breakthrough therapy designation to Keytruda-Lenvima combination for hepatocellular carcinoma

(July 24, 2019)

The FDA granted breakthrough therapy designation to pembrolizumab in combination with lenvatinib as first-line treatment for patients with advanced unresectable hepatocellular carcinoma who are not able to receive locoregional treatment. This is the third... Continue Reading


Bladder Cancer Advocacy Network Announces 2019 Bladder Cancer Research Innovation Awardee

(July 17, 2019)

(July 8, 2019, Bethesda, MD) Today, the Bladder Cancer Advocacy Network (BCAN) announced the recipient of its prestigious Bladder Cancer Research Innovation Award. This year’s awardee is Philip Beachy, Ph.D., Professor of Urology and of Developmental... Continue Reading


Mouthwash reduces radiation-induced oral mucositis pain among patients with head and neck cancer

(July 16, 2019)

A mouthwash consisting of diphenhydramine, lidocaine and antacids significantly reduces oral mucositis pain when used in patients receiving radiation therapy for the treatment of head and neck cancer. Researchers assigned 275 patients with head and neck... Continue Reading


Using the Internet Wisely for Cancer Information

(July 11, 2019)

From Beth Israel Deaconess Medical Center The Internet is simultaneously the best and the worst of tools. This is especially true when related to a cancer patient’s search for support and information. Whereas people used to have to find medical libraries... Continue Reading


New Surgical Technique Shows Potential in Restoring Erectile Function After Radical Prostatectomy

(July 9, 2019)

Cancer Connect News: According to a report from Australian doctors published in the Journal of European Urology minimally invasive end to end nerve grafting can restore erectile function among men who previously underwent radical prostatectomy for prostate... Continue Reading


FDA Approves New Treatment for Multiple Myeloma

(July 5, 2019)

The FDA has granted accelerated approval to selinexor (Xpovio; Karyopharm Therapeutics) tablets in combination with the corticosteroid dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who received ≥4 previous therapies... Continue Reading


NIH study finds long-term increased risk of cancer death following common treatment for hyperthyroidism

(July 2, 2019)

Findings from a study of patients who received radioactive iodine (RAI) treatment for hyperthyroidism show an association between the dose of treatment and long-term risk of death from solid cancers, including breast cancer. The study, led by researchers... Continue Reading


Darzalex Approved for Newly Diagnosed Stem Cell Transplant Ineligible Multiple Myeloma Patients

(July 1, 2019)

Darzalex (daratumumab) in combination with Revlimid (lenalidomide) and dexamethasone has been approved by the US Food and Drug Administration for treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. Approval... Continue Reading


« Previous PageNext Page »